Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIT225 added to Atripla in treatment-naive HIV-1 infection
ACTRN12617000025336Phase 2Completed
- Sponsor
- Biotron Ltd
- Start
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Human immunodeficiency virus infection type 1 comparing BIT225 + Atripla with Placebo + Atripla (2 arms). Primary endpoints: Antiviral activity of BIT225 added to Atripla and Safety and tolerability of BIT225 added to Atripla. Started Apr 2017; status: completed.
02
Drugs
BIT225
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on ACTRN12617000025336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617000025336.